JSR Life Sciences today announced that KBI Biopharma, Inc. (KBI) and Selexis SA are consolidating as one organization under the KBI name to accelerate innovation and growth for its global biopharma customers.

The new structure will enable integrated, seamless solutions for customers, cell line development through process development, to clinical and commercial cGMP manufacturing services for mammalian programs.

For details, please see the announcement from JSR Life Sciences LLC on URL.

JSR Life Sciences Announces Operational Consolidation of KBI Biopharma, Inc. and Selexis SA to Operate as one Organization, Providing Seamless Experience for Partners | JSR Life Sciences Newsroom